Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES:
I. Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with
acute respiratory distress syndrome.
II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients.
Phase:
Phase 1
Details
Lead Sponsor:
Stony Brook University
Collaborators:
FDA Office of Orphan Products Development State University of New York